| ELTVILLE, Germany, April 27, 2012 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received Marketing Authorisation for Bronchitol from the European Commission. The licence allows the new cystic fibrosis treatment to be made available for patients aged 18 and above as an add-on therapy to the best standard of care in 29 European countries. Pharmaxis CEO Dr Alan Robertson said, "This is a very significant event, which means that patients living with cystic f...continued PXSLY |
Friday, April 27, 2012
Pharmaxis Receives Approval to Market Bronchitol in the EU
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment